Vestal Point Capital, LP
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 14, 2024), Vestal Point Capital, LP reported 58 stock positions worth $1.2 billion. Its top holding was Cytokinetics (CYTK) at 12.5% of the portfolio, followed by Jazz Pharmaceuticals (JAZZ, 11.0%) and Neurocrine Biosciences (NBIX, 8.1%). Compared with Q4 2023, it opened 29 new positions, sold out of 19, added to 17 and reduced 10. The biggest buy was Cytokinetics (CYTK, shares +4200%) and the biggest sale an exit from Inhibrx.
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001974915
- Portfolio Value
- $1.2B (Q1 2024)
- SEC Filing
- 0001974915-24-000005 ↗ filed May 14, 2024
Holdings Value
Holdings 58 stocks · $1.2B
| CYTK Cytokinetics Inc. | 12.47% | 2,150,000 | $150.7M | Add +4200.0% |
| JAZZ Jazz Pharmaceuticals PLC | 10.95% | 1,100,000 | $132.5M | Add +51.7% |
| NBIX Neurocrine Biosciences Inc. | 8.10% | 710,000 | $97.9M | Reduce -11.3% |
| ASND Ascendis Pharma A/S | 6.56% | 525,000 | $79.4M | Reduce -16.0% |
| GMED Globus Medical Inc. Class A | 4.44% | 1,000,000 | $53.6M | Add +25.0% |
| SLNO Soleno Therapeutics Inc. | 4.42% | 1,250,000 | $53.5M | Reduce -3.9% |
| ALNY Alnylam Pharmaceuticals Inc. | 4.33% | 350,000 | $52.3M | Add +900.0% |
| ONC Beone Medicines Ltd.-ADR filed as BEIGENE LTD | 4.20% | 325,000 | $50.8M | New |
| NARI Inari Medical Inc. | 3.17% | 800,000 | $38.4M | New |
| APLT Applied Therapeutics Inc. | 2.87% | 5,110,000 | $34.7M | Add +23.0% |
| LQDA Liquidia Corp. | 2.44% | 2,000,000 | $29.5M | Add +95.1% |
| ALXO Alx Oncology Holdings Inc. | 2.41% | 2,610,000 | $29.1M | Add +57.7% |
| AZN Astrazeneca PLC-Spons ADR | 2.24% | 400,000 | $27.1M | Add +60.0% |
| QURE Uniqure NV | 2.03% | 4,725,000 | $24.6M | Add +20.4% |
| INSM Insmed Inc. | 1.68% | 750,000 | $20.3M | Reduce -16.7% |
| ARGX Argenx SE - ADR | 1.63% | 50,000 | $19.7M | New |
| XENE Xenon Pharmaceuticals Inc. | 1.42% | 400,000 | $17.2M | Add +128.6% |
| TGTX TG Therapeutics Inc. | 1.32% | 1,050,000 | $16.0M | New |
| ATXS Astria Therapeutics Inc. | 1.28% | 1,100,000 | $15.5M | New |
| BMRN Biomarin Pharmaceutical Inc. | 1.26% | 175,000 | $15.3M | New |
| ALPN Alpine Immune Sciences Inc. | 1.15% | 350,000 | $13.9M | New |
| SLDB Solid Biosciences Inc. | 1.14% | 1,035,000 | $13.8M | Add +2936.5% |
| DNTH Dianthus Therapeutics Inc. | 1.13% | 455,000 | $13.7M | Add +237.0% |
| APLS Apellis Pharmaceuticals Inc. | 1.09% | 225,000 | $13.2M | New |
| SRPT Sarepta Therapeutics Inc. | 1.07% | 100,000 | $12.9M | New |
| PRAX Praxis Precision Medicines I | 1.06% | 210,000 | $12.8M | New |
| IMTX Immatics NV | 1.04% | 1,200,000 | $12.6M | Reduce -42.9% |
| INCY Incyte Corp. | 0.94% | 200,000 | $11.4M | New |
| MGNX Macrogenics Inc. | 0.88% | 725,000 | $10.7M | New |
| AGIO Agios Pharmaceuticals Inc. | 0.79% | 325,000 | $9.5M | New |
| SWAV Shockwave Medical Inc. | 0.67% | 25,000 | $8.1M | New |
| KRYS Krystal Biotech Inc. | 0.66% | 45,000 | $8.0M | New |
| KALV Kalvista Pharmaceuticals Inc. | 0.64% | 655,000 | $7.8M | New |
| GERN Geron Corp. | 0.60% | 2,200,000 | $7.3M | New |
| ACLX Arcellx Inc. | 0.58% | 100,000 | $7.0M | Add +66.7% |
| EXAS Exact Sciences Corp. | 0.57% | 100,000 | $6.9M | New |
| FULC Fulcrum Therapeutics Inc. | 0.54% | 695,000 | $6.6M | Reduce -32.2% |
| VKTX Viking Therapeutics Inc. | 0.51% | 75,000 | $6.2M | New |
| PASG Passage Bio Inc. | 0.50% | 4,500,000 | $6.1M | New |
| ALLO Allogene Therapeutics Inc. | 0.50% | 1,350,000 | $6.0M | New |
| FATE Fate Therapeutics Inc. | 0.49% | 800,000 | $5.9M | Reduce -38.0% |
| VYGR Voyager Therapeutics Inc. | 0.46% | 600,000 | $5.6M | New |
| RLMD Relmada Therapeutics Inc. | 0.46% | 1,200,000 | $5.6M | Add +943.5% |
| BIO Bio-Rad Laboratories-A | 0.43% | 15,000 | $5.2M | New |
| RARE Ultragenyx Pharmaceutical Inc. | 0.42% | 110,000 | $5.1M | New |
| LYRA Lyra Therapeutics Inc. | 0.41% | 800,000 | $5.0M | Reduce -73.3% |
| LKFT Lakefront Biotherapeutic-ADR filed as GALAPAGOS NV | 0.35% | 130,000 | $4.2M | No change |
| ANRO Alto Neuroscience Inc. | 0.32% | 250,000 | $3.8M | New |
| LXEO Lexeo Therapeutics Inc. | 0.23% | 175,000 | $2.7M | New |
| PRME Prime Medicine Inc. | 0.21% | 360,000 | $2.5M | Add +1672.9% |
| NVAX Novavax Inc. | 0.20% | 500,000 | $2.4M | New |
| PCRX Pacira Biosciences Inc. | 0.19% | 80,000 | $2.3M | Reduce -93.3% |
| ATRA Atara Biotherapeutics Inc. | 0.16% | 2,800,000 | $1.9M | New |
| ACHL Achilles Therapeutics PL-ADR | 0.16% | 1,500,000 | $1.9M | Add +1287.8% |
| CMRX Chimerix Inc. | 0.12% | 1,400,000 | $1.5M | No change |
| RENEO PHARMACEUTICALS INC | 0.04% | 295,375 | $490K | Reduce -26.2% |
| AFMDQ Affimed NV | 0.02% | 55,000 | $292K | Add +0.7% |
| LYEL Lyell Immunopharma Inc. | 0.02% | 130,000 | $290K | New |
Portfolio Sells Q4 2023 → Q1 2024
| INHIBRX INC | Sold out | 0.00% | −6.16 |
| MRK Merck & Co. Inc. | Sold out | 0.00% | −4.62 |
| PCRX Pacira Biosciences Inc. | Reduce -93.3% | 0.19% | −4.10 |
| CBAY Cymabay Therapeutics Inc. | Sold out | 0.00% | −4.07 |
| PCVX Vaxcyte Inc. | Sold out | 0.00% | −3.49 |
| NBIX Neurocrine Biosciences Inc. | Reduce -11.3% | 8.10% | −3.07 |
| VRDN Viridian Therapeutics Inc. | Sold out | 0.00% | −2.31 |
| RVMD Revolution Medicines Inc. | Sold out | 0.00% | −2.20 |
| BIIB Biogen Inc. | Sold out | 0.00% | −2.06 |
| EW Edwards Lifesciences Corp. | Sold out | 0.00% | −1.82 |
| ASND Ascendis Pharma A/S | Reduce -16.0% | 6.56% | −1.78 |
| CRNX Crinetics Pharmaceuticals Inc. | Sold out | 0.00% | −1.70 |
| SNY Sanofi-ADR | Sold out | 0.00% | −1.58 |
| NUVL Nuvalent Inc. Class A | Sold out | 0.00% | −1.56 |
| IMTX Immatics NV | Reduce -42.9% | 1.04% | −1.30 |
| INSM Insmed Inc. | Reduce -16.7% | 1.68% | −1.27 |
| LYRA Lyra Therapeutics Inc. | Reduce -73.3% | 0.41% | −1.25 |
| SLNO Soleno Therapeutics Inc. | Reduce -3.9% | 4.42% | −1.12 |
| AEROVATE THERAPEUTICS INC | Sold out | 0.00% | −0.96 |
| REGN Regeneron Pharmaceuticals | Sold out | 0.00% | −0.93 |
| ARQT Arcutis Biotherapeutics Inc. | Sold out | 0.00% | −0.92 |
| BLUEBIRD BIO INC | Sold out | 0.00% | −0.31 |
| TEVA Teva Pharmaceutical-SP ADR | Sold out | 0.00% | −0.22 |
| FULC Fulcrum Therapeutics Inc. | Reduce -32.2% | 0.54% | −0.19 |
| PYXS Pyxis Oncology Inc. | Sold out | 0.00% | −0.08 |
| IKENA ONCOLOGY INC | Sold out | 0.00% | −0.07 |
| OVID Ovid Therapeutics Inc. | Sold out | 0.00% | −0.03 |
| RENEO PHARMACEUTICALS INC | Reduce -26.2% | 0.04% | −0.03 |
| FATE Fate Therapeutics Inc. | Reduce -38.0% | 0.49% | −0.03 |
Portfolio Buys Q4 2023 → Q1 2024
| CYTK Cytokinetics Inc. | Add +4200.0% | 12.47% | +12.02 |
| ONC Beone Medicines Ltd.-ADR | New | 4.20% | +4.20 |
| ALNY Alnylam Pharmaceuticals Inc. | Add +900.0% | 4.33% | +3.62 |
| NARI Inari Medical Inc. | New | 3.17% | +3.17 |
| ARGX Argenx SE - ADR | New | 1.63% | +1.63 |
| JAZZ Jazz Pharmaceuticals PLC | Add +51.7% | 10.95% | +1.51 |
| APLT Applied Therapeutics Inc. | Add +23.0% | 2.87% | +1.40 |
| TGTX TG Therapeutics Inc. | New | 1.32% | +1.32 |
| ATXS Astria Therapeutics Inc. | New | 1.28% | +1.28 |
| BMRN Biomarin Pharmaceutical Inc. | New | 1.26% | +1.26 |
| ALPN Alpine Immune Sciences Inc. | New | 1.15% | +1.15 |
| LQDA Liquidia Corp. | Add +95.1% | 2.44% | +1.13 |
| SLDB Solid Biosciences Inc. | Add +2936.5% | 1.14% | +1.12 |
| APLS Apellis Pharmaceuticals Inc. | New | 1.09% | +1.09 |
| SRPT Sarepta Therapeutics Inc. | New | 1.07% | +1.07 |
| PRAX Praxis Precision Medicines I | New | 1.06% | +1.06 |
| DNTH Dianthus Therapeutics Inc. | Add +237.0% | 1.13% | +0.98 |
| INCY Incyte Corp. | New | 0.94% | +0.94 |
| MGNX Macrogenics Inc. | New | 0.88% | +0.88 |
| AGIO Agios Pharmaceuticals Inc. | New | 0.79% | +0.79 |
| SWAV Shockwave Medical Inc. | New | 0.67% | +0.67 |
| KRYS Krystal Biotech Inc. | New | 0.66% | +0.66 |
| KALV Kalvista Pharmaceuticals Inc. | New | 0.64% | +0.64 |
| GERN Geron Corp. | New | 0.60% | +0.60 |
| EXAS Exact Sciences Corp. | New | 0.57% | +0.57 |
| XENE Xenon Pharmaceuticals Inc. | Add +128.6% | 1.42% | +0.57 |
| VKTX Viking Therapeutics Inc. | New | 0.51% | +0.51 |
| PASG Passage Bio Inc. | New | 0.50% | +0.50 |
| ALLO Allogene Therapeutics Inc. | New | 0.50% | +0.50 |
| VYGR Voyager Therapeutics Inc. | New | 0.46% | +0.46 |
| AZN Astrazeneca PLC-Spons ADR | Add +60.0% | 2.24% | +0.46 |
| BIO Bio-Rad Laboratories-A | New | 0.43% | +0.43 |
| RARE Ultragenyx Pharmaceutical Inc. | New | 0.42% | +0.42 |
| RLMD Relmada Therapeutics Inc. | Add +943.5% | 0.46% | +0.41 |
| ANRO Alto Neuroscience Inc. | New | 0.32% | +0.32 |
| LXEO Lexeo Therapeutics Inc. | New | 0.23% | +0.23 |
| ACLX Arcellx Inc. | Add +66.7% | 0.58% | +0.22 |
| NVAX Novavax Inc. | New | 0.20% | +0.20 |
| PRME Prime Medicine Inc. | Add +1672.9% | 0.21% | +0.19 |
| ATRA Atara Biotherapeutics Inc. | New | 0.16% | +0.16 |
| ACHL Achilles Therapeutics PL-ADR | Add +1287.8% | 0.16% | +0.14 |
| LYEL Lyell Immunopharma Inc. | New | 0.02% | +0.02 |
| AFMDQ Affimed NV | Add +0.7% | 0.02% | −0.01 |
| GMED Globus Medical Inc. Class A | Add +25.0% | 4.44% | −0.08 |
| ALXO Alx Oncology Holdings Inc. | Add +57.7% | 2.41% | −0.20 |
| QURE Uniqure NV | Add +20.4% | 2.03% | −0.78 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 68 | $4.3B | BMRN, NBIX, ABVX, UTHR, ELVN |
| Q1 2026 | 90 | $3.6B | RVMD, BMRN, ABVX, NBIX, ARWR |
| Q4 2025 | 75 | $2.7B | ABVX, ACLX, TERN, BMRN, GMED |
| Q3 2025 | 80 | $2.2B | ASND, ACLX, NUVL, ABVX, ALC |
| Q2 2025 | 72 | $1.9B | ACLX, JAZZ, CYTK, NUVL, VERA |
| Q1 2025 | 63 | $1.4B | ACLX, CYTK, INSM, NUVL, VERA |
| Q4 2024 | 73 | $1.7B | JAZZ, CYTK, MRK, ASND, RARE |
| Q3 2024 | 67 | $1.3B | INSM, JAZZ, CYTK, NARI, ACLX |
| Q2 2024 | 60 | $1.3B | JAZZ, CYTK, ASND, RARE, GMED |
| Q1 2024 | 58 | $1.2B | CYTK, JAZZ, NBIX, ASND, GMED |